Year: 2016
Type: review
Abstract: Live attenuated and killed whole-cell vaccines (WCVs) offer promising vaccination strategies against tuberculosis. A number of WCV candidates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or related mycobacterial species are in various stages of preclinical or clinical development. In this review, we discuss the vaccine candidates and key factors shaping the development pathway for live and killed WCVs and provide an update on progress.
Institutions: University of Cape Town, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Max Planck Institute for Infection Biology, University of Geneva, Gates Foundation, Universidad de Zaragoza, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Centro de Investigación Biomédica en Red, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier, Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2415369230